13/10/2017 09:54:16

Trinity Biotech plc to Announce 2017 Third Quarter Financial Results

DUBLIN, Ireland, Oct. 13, 2017 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq:TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report 2017 third quarter financial results on Thursday, October 26, 2017. The Company has scheduled a conference call for that same day, Thursday, October 26, 2017 at 11:00am ET (4:00pm BST) to discuss the results of the quarter.

Interested parties can access the call by dialing:

USA:1-844-861-5499
International:1-412-317-6581
Conference ID #:10113410

A simultaneous webcast of the call can be accessed at:

https://www.webcaster4.com/Webcast/Page/1135/23066

A replay of the call can be accessed until November 2, 2017 by dialing:

USA:1-877-344-7529
International:1-412-317-0088
Conference ID #:10113410

The webcast of the call will be available for 30 days at: 

https://www.webcaster4.com/Webcast/Page/1135/23066

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

Contact

Kevin Tansley

Trinity Biotech plc

(353)-1-2769800

E-mail: kevin.tansley@trinitybiotech.com

Joe Diaz, Joe Dorame and Robert Blum

Lytham Partners, LLC

Investor Relations

602-889-9700

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
15 Jun
PNDORA
Carnegie´s senste negative udmeldning omkring en lille analyse foretaget blandt nogle franchisetager..
30
16 Jun
PNDORA
Som Pandora aktionær er jeg meget tilfreds med ledelsens indsats og de skabte resultater. Ledelsen l..
21
14 Jun
 
Jeg har et par gange øffet over niveauet herinde i dette debatforum. I første omgang skrev jeg til b..
18
18 Jun
PNDORA
              Jeg har lavet en fuld analyse på Pandora, som er en blanding af en regnskabs-analyse o..
17
16 Jun
VELO
Her er mit bud på begivenheder og dato for disse de næste 200 dage. Det bliver en god jul i år som i..
14
16 Jun
VWS
Nu er det jo Vestas der er mindst ramt af prispres, da de selv presser priser ned, da målet er at vi..
14
16 Jun
VWS
http://globenewswire.com/news-release/2018/06/15/1525456/0/en/Vestas-secures-442-MW-order-from-Xcel-..
13
14 Jun
VELO
Endnu et studie med Envarsus er startet op. Denne gang af Washington University School of Medicine. ..
13
19 Jun
VWS
https://www.vestas.com/en/media/company-news?n=1763161#!NewsView
12
14 Jun
PNDORA
Mange har snart mistet så mange penge på pandora, at de eneste smykker de har råd til at købe til ko..
12

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
SANOFI COMPLETES ITS ACQUITISION OF ABLYNX FOLLOWING THE EXPIRATION OF THE SQUEEZE-OUT PROCEDURE
2
Publishing of Sponda's Half Year Financial Report January - June 2018
3
Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
4
BioSolar Signs a Joint Development Agreement with Ferroglobe, the Global Leader in the Supply of Silicon Material
5
Hofseth Biocare ASA: Key information relating to the repair issue

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 June 2018 03:04:40
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180619.1 - EUROWEB1 - 2018-06-20 04:04:40 - 2018-06-20 03:04:40 - 1000 - Website: OKAY